Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study

BACKGROUND: Ranolazine is a second-line drug for the management of chronic coronary syndromes (CCS). Glucose-lowering and endothelial effects have also been reported with this agent. However, whether ranolazine may improve short-term glycemic variability (GV), strictly related to the prognosis of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nusca, Annunziata, Bernardini, Federico, Mangiacapra, Fabio, Maddaloni, Ernesto, Melfi, Rosetta, Ricottini, Elisabetta, Piccirillo, Francesco, Manfrini, Silvia, Ussia, Gian Paolo, Grigioni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741377/
https://www.ncbi.nlm.nih.gov/pubmed/35005029
http://dx.doi.org/10.1155/2021/4952447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741377/
https://www.ncbi.nlm.nih.gov/pubmed/35005029
http://dx.doi.org/10.1155/2021/4952447

Ejemplares similares